Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2013-ITN | Award Amount: 3.82M | Year: 2014
Soil, water, and precious metals are major natural resources present at the Earths terrestrial surface and their efficient management is essential for future sustainable development. Their availability is regulated by massive biogeochemical transformations that take place as the chemical elements move from rock to soil, into plants, through ground water, into river water, and into ore deposits. These precious resources are currently being exploited to an extent that is unprecedented in the history of our planet. We will make use of recent technological advances, in the form of novel mass-spectrometric methods, that have the as-yet unrealised capacity to make fundamental advances in understanding the formation of these resources. The understanding developed with these new tools will ultimately guide the sustainable exploitation of Earth surface environments. We will train young researchers in these ISOtopic tools as NOvel Sensors of Earth surface resources (IsoNose) through this European Initial Training Network. Long-term collaboration to train this new generation of scientists will be initiated by instrument manufacturers, academic specialists in method development and applications, private sector participants from the environmental, material certification, and metal ore resources fields. The researchers will use IsoNose as a platform to lead this emerging field into new areas, including the geosciences, environmental forensics, biomedical sciences, and mineral resource prospecting.
Scigelova M.,Thermo Fisher Scientific
Molecular & cellular proteomics : MCP | Year: 2011
This article provides an introduction to Fourier transform-based mass spectrometry. The key performance characteristics of Fourier transform-based mass spectrometry, mass accuracy and resolution, are presented in the view of how they impact the interpretation of measurements in proteomic applications. The theory and principles of operation of two types of mass analyzer, Fourier transform ion cyclotron resonance and Orbitrap, are described. Major benefits as well as limitations of Fourier transform-based mass spectrometry technology are discussed in the context of practical sample analysis, and illustrated with examples included as figures in this text and in the accompanying slide set. Comparisons highlighting the performance differences between the two mass analyzers are made where deemed useful in assisting the user with choosing the most appropriate technology for an application. Recent developments of these high-performing mass spectrometers are mentioned to provide a future outlook. Source
Galperin M.Y.,U.S. National Center for Biotechnology Information |
Rigden D.J.,University of Liverpool |
Fernandez-Suarez X.M.,Thermo Fisher Scientific
Nucleic Acids Research | Year: 2015
The 2015 Nucleic Acids Research Database Issue contains 172 papers that include descriptions of 56 new molecular biology databases, and updates on 115 databases whose descriptions have been previously published in NAR or other journals. Following the classification that has been introduced last year in order to simplify navigation of the entire issue, these articles are divided into eight subject categories. This year's highlights include RNA-central, an international community portal to various databases on noncoding RNA; ValidatorDB, a validation database for protein structures and their ligands; SASBDB, a primary repository for smallangle scattering data of various macromolecular complexes; MoonProt, a database of 'moonlighting' proteins, and two new databases of protein-protein and other macromolecular complexes, ComPPI and the Complex Portal. This issue also includes an unusually high number of cancer-related databases and other databases dedicated to genomic basics of disease and potential drugs and drug targets. The size o f NAR online Molecular Biology Database Collection, http://www.oxfordjournals.org/nar/database/a/, remained approximately the same, following the addition of 74 new resources and removal of 77 obsolete web sites. The entire Database Issue is freely available online on the Nucleic Acids Researchweb site (http://nar.oxfordjournals.org/). Source
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.55M | Year: 2015
MASSTRPLAN will train the next generation of interdisciplinary research leaders in advanced molecular analytical techniques to detect oxidized phospholipids & proteins in biological & clinical samples, evaluate their biochemical roles in inflammation, and translate these findings to develop new diagnostic tools. Chronic inflammatory diseases such as diabetes, cardiovascular disease (CVD) & cancer are major causes of mortality and cost the EU economy dearly in healthcare and lost working time; CVD alone is estimated to be responsible for 47% of deaths and to cost the EU 196 billion a year. Scientists able to develop advanced analytical tools for detecting oxidative biomolecule modifications and assessing their contribution to cell dysfunction & disease are urgently needed. The objectives of MASSTRPLAN are to 1) train early stage researchers (ESRs) in advanced and novel chromatography, mass spectrometry, and complementary techniques including microscopy and bioinformatics to detect challenging heterogeneous biomolecule modifications and determine their functional effects; 2) give ESRs a broad perspective on relevance & mechanisms of oxidative modifications in pathophysiology and biotechnology; 3) enable ESRs trained in technology development to engage effectively with the clinical sector; and 4) train ESRs in translational and development skills to produce new protocols, materials and commercializable diagnostic tools. The ETN will achieve this by bringing together 10 beneficiaries and 15 partners from academic, industrial and healthcare organizations working in analytical, bioinformatic, biological, clinical & biotech fields to provide multidisciplinary, cross-sector training. Extensive mobility, industrial secondments and network-wide training will yield a cohort of analytical scientists with the unique theoretical, technological, and entrepreneurial skill set to yield new understanding of oxidative inflammatory disorders, leading to better tools and therapies.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: FETOPEN-1-2014 | Award Amount: 5.04M | Year: 2015
Systems medicine designates the application of global approaches to human health and disease. Genomic technologies, especially next-generation sequencing, are already pioneering this new area. There is an urgent need to advance proteomics technologies to a similar level. This will help revolutionize diagnosis and prognosis based on the expression levels and modifications of proteins in cells, tissues, organoids or body fluids. Our vision is to make mass spectrometry so robust and powerful that it will be present in every biological laboratory and in every clinic. The applicants are leaders in proteomics technologies from academia and industry and have an out-standing track-record in advancing both instrumentation as well as its application in biological and disease contexts. Here we come together to develop breakthrough technology capable of more than a factor ten improvement in parameters of performance of the mass spectrometric workflow, enabling patient-oriented proteome profiling. The proteomics workflow will be automated, multiplexed and made industrial strength - ready for high-throughput and in-depth clinical applications. Importantly, in addition to the identification of the main protein representative of a gene, we aim to routinely identify and quantify protein modifications and isoforms by using multidimensional approaches, including new separation, enrichment and fragmentation technologies. The breakthroughs aimed for will generate larger more biologically relevant data. This data will be merged with other omic data and mined using machine learning technologies. Our results will establish the role mass spectrometry in systems medicine, making all workflows and mass spectrometry platforms available to the community. They will be used as the basis of myriad applications in biomedicine, even in the clinic. This in turn will lead to a new eco-system around improved diagnosis, elucidations of disease mechanisms and drug action.